New antibiotics for the treatment of serious infections in intensive care unit patients.
Curr Med Res Opin. 2019 Feb 14;:1
Authors: Leone S, Cascella M, Pezone I, Fiore M
Nowadays, the infections of patients admitted to Intensive Care Units (ICUs) are one of the major public health problems; this is due to several factors, in primis an increase in antibiotic resistance and the inappropriate use of antibiotics. This editorial focuses on both new antibiotics approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in the last decade (2010-2019), and on agents in advanced phase of development that have been developed, or are already approved, for the treatment of serious infections due to multidrug-resistant (MDR) bacteria, both Gram-positive (GPB) and Gram-negative (GNB) bacteria. An adequate knowledge of the new antibiotics will reduce their inappropriate use with the consequent reduction of the onset of new resistance and decreasing health care costs.
PMID: 30760041 [PubMed - as supplied by publisher]